BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2227-2236

  Duong, Hong Quan ^a,b   Hwang, Jae Seok ^a,c   Kim, Hee Jeong ^a   Seong, Yeon Sun ^b   Bae, Insoo ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Adenosine monophosphate activated protein kinase; Apoptosis; BML 275; DNA damage; G2 M arrest; Pancreatic cancer

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BML 275; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; EPITHELIUM CELL; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; ENZYME ACTIVATION; EPITHELIAL CELLS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE SILENCING; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; PYRAZOLES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE;

EID: 84869859134     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1672     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Keighley MR: Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18: 7-30, 2003.
3. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
4. Hardie DG and Carling D: The AMP-activated protein kinase - fuel gauge of the mammalian cells? Eur J Biochem 246: 259-273, 1997. (Pubitemid 27232500)
5. Hardie DG, Scott JW, Pan DA and Hudson ER: Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546: 113-120, 2003. (Pubitemid 36782291)
6. Carling D: The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 29: 18-24, 2004.
7. Hardie DG: The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117: 5479-5487, 2004.
8. Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005. (Pubitemid 43960587)
9. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG and Hardie DG: Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2: 9-19, 2005. (Pubitemid 43239821)
10. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR and Witters LA: The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280: 29060-29066, 2005. (Pubitemid 41161355)
11. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M and Carling D: Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2: 21-33, 2005. (Pubitemid 43239822)
12. Campàs C, Lopez JM, Santidrián AF, Barragán M, Bellosillo B, Colomer D and Gil J: Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101: 3674-3680, 2003. (Pubitemid 36857958)
13. Kefas BA, Cai Y, Kerchhofs K, Ling Z, Martens G, Heimberg H, Pipeleers D and Van de Casteele M: Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 68: 409-416, 2004. (Pubitemid 38887423)
14. Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S and Nishizaki T: Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relawant to activation of AMP-activated protein kinase. Biochem Pharmacol 67: 2005-2011, 2004. (Pubitemid 38591388)
15. Rattan R, Giri S, Singh AK and Singh I: 5-aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005. (Pubitemid 41713917)
16. Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghlchi SM, El Meskini R, Ronnett GV, Townsend CA and Kuhajda FP: Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67: 2964-6971, 2007.
17. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D and Trajkovic V: Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302, 2007. (Pubitemid 46791062)
18. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, Koda T, Kamijo T, Nakagamara A and Kizaki H: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979-3987, 2008.
19. Senqupta TK, Leclerc GM, Hsieh-Kinser TT, leclerc GJ, Singh I and Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6: 46, 2007.
20. Baumann P, Mandl-Weber S, Emmerich B, Straka C and Schmidmaier R: Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs 18: 405-410, 2007. (Pubitemid 46712403)
21. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A and Collins SP: AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8: 733-741, 2009.
22. Vuvicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E, Sumarac-Dumanovic M, Micic D and Trajkovic V: AMP-activated protein kinase-dependent and-independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol 77: 1684-1693, 2009.
23. Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, Obeid LM, Hannun YA and Hsu YT: AMPK inhibitor compound C stiumulates ceramine production and promotes BAx redistribution and apoptosis in MCF-7 breast carcinoma cells. J Lipid Res 50: 2389-2397, 2009.
24. Jang JH, Lee TJ, Yang ES, Min do S, Kim YH, Kim SH, Choi YH, Park JW, Choi KS and Kwon TK: Compound C sensitizes caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1. Exp Cell Res 316: 2194-2203, 2010.
25. Zhu Q, Shen B, Zhang B, Zhang W, Chin SH, Jin J and Liao DF: Inhibition of AMP-activated protein kinase pathway sensitizes human leukemia K562 cells to nontoxic concentration of doxorubicin. Mol Cell Biochem 340: 275-281, 2010.
26. Kim HS, Hwang JT, Yun H, Chi SG, Lee SJ, Kang I, Yoon KS, Choe WJ, Kim SS and Ha J: Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283: 3731-3742, 2008.
27. Collins K, Jacks T and Pavletich NP: The cell cycle and cancer. Proc Natl Acad Sci USA 94: 2776-2778, 1997. (Pubitemid 27157209)
28. Buolamwini JK: Cell cycle molecular targets in novel anti-cancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
29. Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V and Strnad M: Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv Exp Med Biol 457: 341-353, 1999. (Pubitemid 129735328)
30. Pines J: Four-dimensional control of the cell cycle. Nat Cell Biol 1: E73-E79, 1999.
31. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001. (Pubitemid 32458690)
32. Ueda S, Nakamura H, Masutani H, Sasada T, Takabayashi A, Yamaoka Y and Yodoi J: Baicalin induces apoptosis via mitochondrial pathway as prooxidant. Mol Immunol 38: 781-791, 2002. (Pubitemid 34158881)
33. Beckman KB and Ames BN: Oxidative decay of DNA. J Biol Chem 272: 19633-19636, 1997. (Pubitemid 27340047)
34. Cadet J, Delatour T, Douki T, Gasparutto D, Pouget JP, Ravanat JL and Sauvaigo S: Hydroxyl radicals and DNA base damage. Mutal Res 424: 9-21, 1999. (Pubitemid 29101604)
35. Vilenchik MM and Knudson AG: Endogenous DNA double-strand breaks:production, fidelity of repair and induction of cancer. Proc Natl Acad Sci USA 100: 12871-12876, 2003. (Pubitemid 37339992)
36. Furukawa T, Duquid WP, Rosenberg L, Viallet J, Galloway DA and Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 148: 1763-1770, 1996. (Pubitemid 26171674)
37. Duong HQ, Kim HJ, Kang HJ, Seong YS and Bae I: ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol Rep 27: 182-188, 2012.
38. Hardie DG, Carling D and Carlson M: The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cells? Annu Rev Biochem 67: 821-855, 1998. (Pubitemid 28411146)
39. Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG, Kim SS and Ha J: AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 278: 39653-39661, 2003. (Pubitemid 37248526)
40. Yun H, Lee M, Kim SS and Ha J: Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 280: 9963-9972, 2005. (Pubitemid 40395845)
41. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M and Esumi H: Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 21: 6082-6090, 2002.
42. Esumi H, Izuishi K, Kato K, Hashimoto K, Kurashima Y, Kishimoto A, Ogura T and Ozawa T: Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase dependent manner. J Biol Chem 277: 32791-32798, 2002. (Pubitemid 34984788)
43. Shaw MM, Gurr WK, McCrimmon RJ, Schorderer DF and Sherwin RS: 5′AMP-activated protein kinase alpha deficiency enhances stress-induced apoptosis in BHK and PC12 cells. J Cell Mol Med 11: 286-298, 2007. (Pubitemid 46693327)
44. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
45. Luo J, Solimini NL and Elledqe SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837, 2009.
46. Lobrich M and Jeggo PA: The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7: 861-869, 2007. (Pubitemid 350006255)
47. Smits VA and Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 1519: 1-12, 2001.
48. Gotoh T, Ohsumi K, Matsui T, Takisawa H and Kishimoto T: Inactivation of the checkpoint kinase Cds1 is dependent on cyclin B-Cdc2 kinase activation at the meiotic G2/M-phase transition in xenopus oocytes. J Cell Sci 114: 3397-3406, 2001. (Pubitemid 32998914)
49. Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L and Baskaran R: Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 279: 25813-25822, 2004. (Pubitemid 38756846)
50. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W and Tonghua L: Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8: 125, 2009.
51. Kreutzer JN, Ruzzene M and Guerra B: Enhancing chemosensitivity to gemcitabine via RNA interfence targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer 10: 40, 2010.
52. Danilov AV, Neupane D, Nagaraja AS, Feofanova EV, Humphries LA, DiRenzo J and Korc M: DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PloS One 6: e26815, 2011.
53. Hagmann W, Jesnowski R and Löhr JM: Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 12: 740-747, 2010.
54. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W and Kasuga M: Role of Akt in growth and survival of Panc-1 pancreatic cancer cells. Pancreas 24: 42-46, 2002. (Pubitemid 34019658)